



## Supplementary Figure 2

(A) Observed mean ( $\pm$ SE) LAG-3<sup>+</sup> and CD3<sup>+</sup> cell counts in skin of healthy participants following DTH re-challenge at day 29. (B) Observed mean ( $\pm$ SE) induration diameter following DTH challenge pre- and post-treatment in healthy participants.

A



B



\*Study day 0 = week 0 baseline biopsy; Study day 4 = week 4 biopsy and is 72 hours since dosing day 1 (day 29).

†Day -26 = 48-hour assessment of induration after initial PPD challenge; day 1 = GSK2831781 or placebo dosing; day 2 = PPD re-challenge; days 4, 8, 15, and 22 = assessment of induration.

ADA, anti-drug antibodies; DTH, delayed type hypersensitivity; HP, healthy participants; SE, standard error.